Nkcfo LLC Has $1.13 Million Stock Position in Natera, Inc. (NASDAQ:NTRA)

Key Points

• Nkcfo LLC sold 3,530 shares of Natera, reducing its holdings by 30.6%, leaving them with 8,000 shares worth approximately $1,131,000.
• Insider sales included Solomon Moshkevich selling 3,000 shares and Gail Boxer Marcus selling 4,299 shares, marking notable decreases in their ownership stakes.
• Despite these insider actions, analysts maintain a consensus rating of "Moderate Buy" for Natera, with price targets ranging from $184.63 to $218.00.

Nkcfo LLC reduced its stake in Natera, Inc. (NASDAQ:NTRA - Free Report) by 30.6% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 8,000 shares of the medical research company's stock after selling 3,530 shares during the quarter. Nkcfo LLC's holdings in Natera were worth $1,131,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD increased its position in shares of Natera by 134.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company's stock valued at $1,067,327,000 after purchasing an additional 3,871,862 shares during the last quarter. Norges Bank purchased a new position in Natera during the 4th quarter worth $224,040,000. Wellington Management Group LLP grew its position in Natera by 15.7% during the 4th quarter. Wellington Management Group LLP now owns 3,240,041 shares of the medical research company's stock worth $512,898,000 after purchasing an additional 439,778 shares during the last quarter. Franklin Resources Inc. lifted its stake in shares of Natera by 40.0% in the 4th quarter. Franklin Resources Inc. now owns 1,538,875 shares of the medical research company's stock worth $243,604,000 after acquiring an additional 439,540 shares during the period. Finally, SG Americas Securities LLC lifted its stake in shares of Natera by 8,233.5% in the 1st quarter. SG Americas Securities LLC now owns 397,924 shares of the medical research company's stock worth $56,270,000 after acquiring an additional 393,149 shares during the period. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Natera

In other Natera news, CEO Steven Leonard Chapman sold 6,111 shares of the stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $157.10, for a total transaction of $960,038.10. Following the transaction, the chief executive officer owned 179,071 shares in the company, valued at $28,132,054.10. This trade represents a 3.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Michael Burkes Brophy sold 3,045 shares of the stock in a transaction that occurred on Tuesday, July 29th. The shares were sold at an average price of $137.40, for a total value of $418,383.00. Following the transaction, the chief financial officer owned 65,430 shares in the company, valued at approximately $8,990,082. This trade represents a 4.45% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 48,936 shares of company stock worth $7,483,846. Corporate insiders own 7.60% of the company's stock.

Natera Stock Performance

Shares of NASDAQ:NTRA traded down $4.03 during trading hours on Thursday, hitting $136.93. 530,528 shares of the company's stock traded hands, compared to its average volume of 1,488,340. Natera, Inc. has a 52 week low of $92.14 and a 52 week high of $183.00. The company has a market cap of $18.70 billion, a price-to-earnings ratio of -93.16 and a beta of 1.73. The company's fifty day simple moving average is $158.12 and its two-hundred day simple moving average is $156.45.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.59) by $0.09. The business had revenue of $501.83 million during the quarter, compared to analyst estimates of $446.68 million. Natera had a negative net margin of 10.36% and a negative return on equity of 18.29%. The firm's revenue was up 36.5% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.56) earnings per share. On average, analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Wall Street Analyst Weigh In

NTRA has been the subject of several recent analyst reports. Piper Sandler raised their price objective on shares of Natera from $205.00 to $210.00 and gave the company an "overweight" rating in a research note on Thursday, May 15th. Barclays lifted their price target on shares of Natera from $160.00 to $190.00 and gave the stock an "overweight" rating in a report on Friday, May 9th. UBS Group lifted their price target on shares of Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a report on Friday, May 9th. Evercore ISI raised shares of Natera to a "strong-buy" rating and set a $170.00 price target on the stock in a research note on Monday. Finally, Wall Street Zen lowered Natera from a "hold" rating to a "sell" rating in a research note on Saturday, May 17th. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $183.76.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.